NCT05574881 2024-02-26
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
Phase 1/2 Unknown
Clinical Trials
11 trialsNCT06243185 2024-02-06
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
Peking Union Medical College Hospital
Phase 2 Unknown
NCT06133088 2023-11-15
Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05806671 2023-04-10
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03772353 2023-03-07
PLEASURABLE
Fudan University
Phase 1/2 Unknown
NCT05480280 2023-02-28
FIND
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT05577442 2022-10-19
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05586841 2022-10-19
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study
Beijing 302 Hospital
Phase 1 Unknown
NCT05577923 2022-10-13
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Phase 2 Unknown
NCT05512416 2022-08-23
Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer
The Affiliated Hospital of Qingdao University
Phase 2 Unknown
NCT05512780 2022-08-23
Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage â…¡-â…¢ HR-positive/HER2-negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Unknown